424B3FORM 424B3
May 19, 2026Final prospectus0001437749-26-017796
All companies
Start with eToro424B4Sep 27, 2019
Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders Form S-1 for Vaxart INC filed 05/08/2026 Vaxart, Inc. – 0001437749-26-015961 – S-1 [S-1/A] Vaxart, Inc. Amends IPO Registration Statement
Vaxart Inc
VXRTIPO Upcoming
IPO UpcomingUnited States(OTC)0 markets
Official IPO
Priced· OTC· Listing market: United StatesIPO date
To be announced
Final IPO price
To be announced
Shares offered
To be announced
IPO raise
To be announced
Sources: sec-harvest
No live market is quoted for Vaxart Inc yet. Get in line for IPO-day access through a broker in the meantime.
eToro
Invest in stocks once they list with eToro
Trade stocks, ETFs and crypto from one simple account.
Vaxart Inc IPO public float & lock-up
Public float and locked shares extracted from Vaxart Inc's SEC prospectus. Shares shown are eligible to trade — lock-up expiry does not mean holders have sold or will sell.
Total shares (FD)
38.35M
Public float
22.57M
Locked
15.79M
IPO raise
—
Next unlock
—
Needs review: Could not extract a detailed lock-up release schedule.
Financials
ProfitableFrom SEC filings, latest FY ending Dec 31, 2025 · CIK 0000072444.
Revenue · +726.68% YoY
$237.26M
Net income
$16.33K
Gross margin
—
Cash
$34.76M
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $237.26M | $28.7M | $7.38M | — | — |
| Operating income | $18.07M | -$66.29M | -$83.35M | -$114.59M | -$72.75M |
| Net income | $16.33K | -$66.95K | -$82.47K | -$107.76M | -$70.47M |
| R&D expense | $201.58M | $74.21M | $68.14M | $81.05M | $48.75M |
| Cash & equivalents | — | — | $34.76M | $44.01M | $143.75M |
| Total assets | $186.08M | $166.39M | $91.83M | $153.85M | $221.17M |
| Total liabilities | $98.28M | $107.46M | $34.03M | $43.25M | $33.64M |
| Shareholders' equity | $87.8M | $58.93M | $57.81M | $110.6M | $187.53M |
About Vaxart Inc
Vaxart is a clinical-stage biotechnology company developing oral tablet vaccines designed to generate mucosal and systemic immune responses.
What the company does
- Uses its oral vaccine platform to develop candidates that can be administered by tablet rather than injection.
- Targets infectious diseases and vaccine categories where easier administration, storage, and distribution could improve access.
- Advances programs through preclinical work, clinical trials, manufacturing development, and regulatory engagement.
Business profile
Vaxart operates in vaccine biotechnology, where clinical efficacy, safety, platform validation, manufacturing scale, and regulatory progress determine commercial potential.
SEC IPO filings
Final prospectusEDGAR filings resolved from VXRT / CIK 0000072444.
May 18, 2026Effective9999999995-26-001690
S-1/AFORM S-1/A
May 18, 2026Amended0001437749-26-017489
S-1FORM S-1
May 8, 2026Filed0001437749-26-015961
Apr 30, 2026Effective9999999995-26-001410
CORRESPfilename1.htm
Apr 29, 2026SEC correspondence0001437749-26-013795
UPLOADfilename1.pdf
Apr 21, 2026SEC correspondence0000000000-26-004034
May 5, 2023Effective9999999995-23-001317
CORRESPfilename1.htm
May 3, 2023SEC correspondence0001437749-23-012326
UPLOADfilename1.pdf
Mar 23, 2023SEC correspondence0000000000-23-002930
UPLOADfilename1.pdf
Jan 29, 2021SEC correspondence0000000000-21-001113
CORRESPfilename1.htm
Jan 27, 2021SEC correspondence0001437749-21-001388
Latest Vaxart Inc IPO news
Recent sourced articles classified for IPO relevance, with platform-access noise filtered out where possible.
NasdaqMay 19, 2026IPO context
Company-specific recent filing/press release (supports IPO-context tracking even though it’s a proxy update rather than pricing/listing).
Vaxart Investor RelationsMay 8, 2026IPO filing
Company-hosted S-1 document with an explicit filing date; strong IPO-file context.
Vaxart Investor RelationsIPO filing
Direct company-hosted S-1 filing link (primary IPO-related document).
StockTitanIPO context
Amended S-1 update related to the same IPO registration workflow.
Vaxart Inc IPO — frequently asked questions
- When is Vaxart Inc's IPO?
- Vaxart Inc has not announced an official IPO date yet — it is still privately held. We update this page as soon as an IPO date, filing or price range is reported.
- What is Vaxart Inc's expected IPO price?
- Vaxart Inc's IPO price has not been set yet. The price range is usually disclosed in the final prospectus, shortly before the company lists.
- Is Vaxart Inc publicly traded?
- Not yet — Vaxart Inc is still a private company, so its shares aren't available on public exchanges. IPO Tracker monitors pre-IPO markets, IPO filings and the IPO calendar, so Vaxart Inc's pre-IPO price and IPO date will appear here as soon as they're available.